Printer Friendly

Browse Lung cancer, Small cell topic

Articles

1-300 out of 317 article(s) nextnext page
Title Author Type Date Words
United States : Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Nave RET Fusion-Positive Non-Small Cell Lung Cancer. Dec 16, 2019 357
United States : CHMP Issues Positive Opinion to Expand CYRAMZA (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Dec 16, 2019 504
United States : Data from Exploratory Analysis Show Mercks KEYTRUDA (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status. Dec 14, 2019 434
Switzerland : FDA approves Roches Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer. Dec 9, 2019 442
FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer. Dec 4, 2019 1548
United States : Mercks KEYTRUDA (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy. Nov 30, 2019 311
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer. Nov 29, 2019 1489
Non-Small Cell Lung Cancer Treatment Global Market by Size, Share, Growth, Trend / Lung Cancer Industry ,Drugs Expansion Strategies, Competitive Landscape, Forecast To 2023. Nov 21, 2019 953
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) - Regeneron Provides Updates on Phase 3 Libtayo[R] (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer -- 5/11/2019. Nov 13, 2019 1613
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) - Regeneron Provides Updates on Phase 3 Libtayo[R] (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer -- 5/11/2019. Nov 6, 2019 1611
AstraZeneca (NYSE: AZN) - Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer -- 28/10/2019. Oct 29, 2019 337
Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer; POSEIDON included both non-squamous and squamous patients and a broad choice of standard chemotherapy ... Oct 29, 2019 1868
Global Small Cell Lung Cancer Pipeline Report 2019: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease. Report Oct 29, 2019 864
United States : Lilly's CYRAMZA (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology. Oct 14, 2019 456
Switzerland : First-line treatment with Tecentrik monotherapy extends survival for certain patients with advanced non-small cell lung cancer compared to chemotherapy. Oct 14, 2019 223
Merck & Company, Inc. (NYSE:MRK) - Merck's KEYTRUDA[R] (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 -- 2/10/2019. Oct 7, 2019 540
Bristol-Myers Squibb Shows Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Oct 1, 2019 149
AstraZeneca Data Shows Tagrisso as the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years. Oct 1, 2019 580
Roche's Satralizumab Achieves Positive Phase III Results in NMOSD: Merck KGaA's tepotinib granted Breakthrough Designation in non-small cell lung cancer. Oct 1, 2019 1712
Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer. Kefeli, Umut; Kaymaz, Samet; Aydin, Dincer; Isik, Deniz; Cabuk, Devrim; Sonkaya, Alper; Acikgoz, Ozg Clinical report Oct 1, 2019 3825
Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years. Sep 30, 2019 2054
United States : Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Financial report Sep 30, 2019 110
United States : Genentechs Tecentriq (Atezolizumab) Improves Overall Survival as a First-Line Monotherapy in Certain People With Advanced Non-Small Cell Lung Cancer. Sep 28, 2019 420
ASTRO: NSAIDs May Offer Benefit to Head & Neck Cancer Patients; Benefit not significant for aspirin use in patients with non-small cell lung cancer undergoing SBRT. Sep 23, 2019 295
AstraZeneca (NYSE: AZN) - Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer -- 9/9/2019. Sep 17, 2019 541
United States : Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients. Financial report Sep 17, 2019 396
United States : Genentechs Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy. Sep 16, 2019 318
Switzerland : Roches Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy. Sep 16, 2019 313
AstraZeneca (NYSE: AZN) - Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer -- 4/9/2019. Sep 11, 2019 457
AstraZeneca (NYSE: AZN) - Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer -- 9/9/2019. Sep 11, 2019 524
Eli Lilly and Company UK (NYSE: LLY) - Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer -- 9/9/2019. Financial report Sep 11, 2019 806
Ipsen - Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE[R]) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer - 8/9/2019. Conference news Sep 11, 2019 619
Switzerland : Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer. Sep 7, 2019 277
European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer. Sep 6, 2019 1496
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 276
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 272
Chugai Pharmaceutical Co., Ltd. - Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer -- 22/8/2019. Aug 27, 2019 727
Non-Small Cell Lung Cancer Market Huge Growth Opportunities and Challenges to Watch in 2019. Aug 22, 2019 950
AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study. Aug 21, 2019 319
Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer. Aug 21, 2019 1680
Genentech (SIX: RO, ROG; OTCQX: RHHBY) - FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors -- 15/8/2019. Aug 20, 2019 645
United States : FDA Approves Genentechs Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors. Aug 19, 2019 666
Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion; Drug also approved to treat metastatic non-small cell lung cancer with ROS1-positive tumors. Aug 19, 2019 327
FDA Approves Genentech's Rozlytrek for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors. Aug 19, 2019 982
Switzerland : FDA approves Roches Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours. Aug 17, 2019 544
FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours. Aug 16, 2019 1528
Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours. Correction notice Aug 16, 2019 1748
AstraZeneca (NYSE: AZN) - Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer -- 9/8/2019. Aug 14, 2019 209
Tagrisso "Significantly Improves" Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer. Aug 12, 2019 606
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer. Aug 9, 2019 1322
AstraZeneca- Imfinzi granted US Orphan Drug Designation for small cell lung cancer -- 12/7/2019. Aug 1, 2019 285
Switzerland : CHMP recommends EU approval of Roches Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Jul 30, 2019 378
CHMP recommends EU approval of Roche's Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Jul 26, 2019 1395
Sequencing Of Circulating Free Dna From Small Cell Lung Cancer Patients. Jul 19, 2019 101
Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer. Jul 17, 2019 599
AstraZeneca - Imfinzi granted US Orphan Drug Designation for small cell lung cancer -- 12/7/2019. Jul 16, 2019 285
Genprex Updates on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer. Jul 8, 2019 470
Genprex Updates on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer. Jul 8, 2019 433
FDA Approves US Merck's Keytruda as Monotherapy for Patients with Metastatic Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy. Jun 21, 2019 678
Merck--FDA Approves Merck's KEYTRUDA[R] (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy--18/6/2019. Jun 20, 2019 338
United Kingdom : Imfinzi is the only immunotherapy to demonstrate overall survival at three years in unresectable Stage III non-small cell lung cancer. Jun 12, 2019 478
Sotio's DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer. Jun 4, 2019 255
AstraZeneca Touts Imfinzi is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer. Jun 4, 2019 768
Five-Year Survival Data for US Merck's Keytruda in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting. Jun 3, 2019 679
Differential Notchl and Notch2 expression in non-small cell lung cancer. Pancewicz, J.; Bernatowicz, PL. Jun 1, 2019 1861
IO Biotech announces Phase 2 of clinical trial for investigational candidate IO102 combined with KEYTRUDA (pembrolizumab) to treat first-line patients with metastatic non-small cell lung cancer. May 15, 2019 271
Pneuma Respiratory and Leads Biolabs enter into partnership for development of immuno-oncology treatment for non-small cell lung cancer. May 15, 2019 264
IO Biotech announces Phase 2 of clinical trial for investigational candidate IO102 combined with KEYTRUDA (pembrolizumab) to treat first-line patients with metastatic non-small cell lung cancer. May 15, 2019 267
Pneuma Respiratory and Leads Biolabs enter into partnership for development of immuno-oncology treatment for non-small cell lung cancer. May 15, 2019 260
United States : European Commission Approves Lorviqua (Lorlatinib) for Certain Adult Patients With Previously-treated Alk-positive Advanced Non-small Cell Lung Cancer. May 11, 2019 567
Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis. Sahin, Songul; Batur, Sebnem; Aydin, Ovgu; Ozturk, Tulin; Turna, Akif; Oz, Buge May 1, 2019 5084
New Insight of Tumor Microenvironment in Non-Small Cell Lung Cancer. Sever, Tolga; Leblebici, Asim; Koc, Altug; Binicier, Cilem; Olgun, Aybuke; Edizer, Deniz Tuna; Ozdem May 1, 2019 6554
SK Biopharmaceuticals and twoXAR Team to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer. Apr 22, 2019 465
Vizimpro Receives Marketing Authorization in European Union for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer. Apr 8, 2019 208
Bristol-Myers Squibb Releases Long-Term Survival Results from Pooled Analyses of Opdivo in Previously-Treated Non-Small Cell Lung Cancer Patients. Apr 5, 2019 107
United States : FDA Approves Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer. Mar 25, 2019 404
Switzerland : FDA approves Roches Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer. Mar 25, 2019 377
FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer. Mar 21, 2019 390
Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. Mar 19, 2019 293
Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. Mar 19, 2019 289
European Commission Approves US Merck's Keytruda (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer. Mar 15, 2019 497
Pfizer Receives Positive CHMP Opinion for Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. Mar 4, 2019 444
FDA Grants Priority Review to US Merck's Supplemental Biologics License Application for Keytruda Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer. Feb 22, 2019 413
Advaxis Enrolls First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer. Feb 19, 2019 413
European Medicines Agency Adopts Positive Opinion for US Merck's Keytruda in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Feb 4, 2019 430
Innovation and Value Initiative Releases Open-Source Model for Assessing Value of EGFR+ Non-Small Cell Lung Cancer Treatment Sequences. Jan 31, 2019 582
United States : Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of. Report Dec 10, 2018 105
United States : FDA Grants Priority Review to Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer. Dec 10, 2018 279
Roche PH launches immunotherapy for previously treated non-small cell lung cancer. Dec 6, 2018 577
European Commission Approves Alunbrig for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe. Nov 28, 2018 351
Roche (Philippines) Inc. launches immunotherapy for previously treated non-small cell lung cancer. Nov 26, 2018 610
United States : Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer. Nov 6, 2018 207
FDA Approves US Merck's Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Nov 2, 2018 353
Switzerland : Roches Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer. Oct 25, 2018 633
Switzerland : Roches Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone. Oct 25, 2018 133
Genentech's Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone. Oct 24, 2018 183
Japan : Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer. Oct 20, 2018 248
Spain : PharmaMar presents the Overall Survival data from the Phase I/II Study of lurbinectedin in combination with doxorubicin for relapsed Small Cell Lung Cancer. Oct 20, 2018 233
Bristol-Myers Squibb Says Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer. Oct 12, 2018 696
US FDA Approves Vizimpro for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer. Oct 1, 2018 699
Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy. Liu, Shuai; Chen, Peng; Liu, Yan-Wei; Gu, Xue-Nan; Qiu, Xiao-Guang; Li, Bo Report Oct 1, 2018 4742
Takeda Receives Positive CHMP Opinion Recommending Alunbrig (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib. Sep 24, 2018 1082
FDA Grants Priority Review to Merck's Application for Keytruda (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS a[per mille][yen sign]1%) ... Sep 13, 2018 349
Innovent Biologics treats first patient under phase III clinical trial of sintilimab for non-squamous non-small cell lung cancer (NSCLC). Sep 11, 2018 266
Innovent Biologics treats first patient under phase III clinical trial of sintilimab for non-squamous non-small cell lung cancer (NSCLC). Sep 11, 2018 262
Prognostic analysis of surgical-pathologic N1 disease in non-small cell lung cancer: Single-center experience with 276 cases. Yazgan, Serkan; Ucvet, Ahmet; Gursoy, Soner; Samancilar, Ozgur; Guvenc, Ezgi Cimen Sep 1, 2018 3728
Application of the Next-Generation Sequencing Technology to Reveal Mechanism of Small Cell Lung Cancer Transformation from Adenocarcinoma. Zhou, Yong-Zhao; Jin, Jing; Tian, Pan-Wen; Li, Wei-Min Letter to the editor Sep 1, 2018 771
United States : Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer. Aug 27, 2018 685
Roche receives FDA Approval for Cobas EGFR Mutation Test v2 as Companion Diagnostic with Iressa in First-Line Treatment of Patients with Non-Small Cell Lung Cancer. Aug 27, 2018 378
Roche awarded US FDA's approval for cobas EGFR Mutation Test v2 with IRESSA for treating non-small cell lung cancer. Aug 24, 2018 284
Roche awarded US FDA's approval for cobas EGFR Mutation Test v2 with IRESSA for treating non-small cell lung cancer. Aug 24, 2018 280
United States : Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer. Aug 24, 2018 685
United Kingdom : Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer. Aug 23, 2018 342
Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dong, Jie; Wang, Xu; Yu, Yu; Yan, Xu; Cui, Jiu-Wei Report Aug 20, 2018 3710
PharmaMar wins US FDA orphan drug designation for lurbinectedin for small cell lung cancer. Aug 6, 2018 196
PharmaMar wins US FDA orphan drug designation for lurbinectedin for small cell lung cancer. Aug 6, 2018 192
Comparison of the Effects of the Sixth and Seventh TNM Staging on Survival in Operable Non-Small Cell Lung Cancer. Kuzucuoglu, Mustafa; Karamustafaoglu, Yekta Altemur; Yoruk, Yener Aug 1, 2018 3051
United States : FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer. Jul 6, 2018 265
Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. Saxena, Ashish Report Jul 1, 2018 1764
China,United States : China National Drug Administration Approves Countrys First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC). Jun 18, 2018 557
United States : Mercks KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study. Report Jun 13, 2018 280
United States : Mercks KEYTRUDA (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study. Jun 13, 2018 374
United States : FDA Expands Lilly's ALIMTA (pemetrexed) Label to Include Combination with KEYTRUDA (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression. Jun 9, 2018 546
Genentech's Tecentriq Plus Chemotherapy Decreases the Risk of Disease Worsening or Death for People with Advanced Squamous Non-Small Cell Lung Cancer in Phase III IMpower131 Study. Jun 7, 2018 282
Switzerland : Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer. Jun 5, 2018 282
Human bronchial epithelial cells as a good control for evaluation potential therapeutic Notch signaling in non-small cell lung cancer. Pancewicz, J.; Bernatowicz, P.L.; Golec, P. Report Jun 1, 2018 2562
United States : Mercks KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial. May 29, 2018 230
Switzerland : Follow-up phase III data showed Roches Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death. May 18, 2018 413
United Kingdom : US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer. Apr 21, 2018 302
Clinically Significant Dysregulation of hsa-miR-30d-5p and hsa-let-7b Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer. Hosseini, Sayed Mostafa; Soltani, Bahram Mohammad; Tavallaei, Mahmoud; Mowla, Seyed Javad; Tafsiri, Apr 1, 2018 4541
AbbVie Will Not Seek Accelerated Approval of Rova-T for Third-Line Treatment of Certain Patients with Relapsed/Refractory Small Cell Lung Cancer. Mar 26, 2018 243
United States : OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment. Mar 20, 2018 292
IO Biotech & MSD partnership to evaluate the IO102 and KEYTRUDA combination for non-small cell lung cancer. Mar 12, 2018 250
IO Biotech & MSD partnership to evaluate the IO102 and KEYTRUDA combination for non-small cell lung cancer. Mar 12, 2018 246
United States : OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment. Mar 3, 2018 307
Japan : Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer. Feb 24, 2018 275
United Kingdom : US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer. Feb 20, 2018 322
AstraZeneca wins US FDA approval for IMFINZI (durvalumab) for treating unresectable Stage III non-small cell lung cancer. Feb 19, 2018 309
AstraZeneca wins US FDA approval for IMFINZI (durvalumab) for treating unresectable Stage III non-small cell lung cancer. Feb 19, 2018 305
Japan : Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Feb 8, 2018 352
Japan : Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, TECENTRIQ Intravenous Infusion 1200mg for the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer. Jan 20, 2018 370
Evaluation of Serum-Paired miRNA Ratios for Early Diagnosis of Non-Small Cell Lung Cancer Using Quantum Dot-Based Suspension Array. Fan, Lihong; Chen, Hao; Teng, Junliang; Li, Dan; Wang, Changhui; Xia, Qing; Su, Bo; Qi, Huiwei Jan 1, 2018 4044
In Vitro and In Vivo Inhibitory Effect of Gujin Xiaoliu Tang in Non-Small Cell Lung Cancer. Hou, Chao; Zhou, Dai-Han; Wu, Yong-Jian; Dai, Xiao-Jun; Wang, Qing-Ying; Wu, Yin- Qiu; Zhang, En-Xin Jan 1, 2018 5929
Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C. Morris; Karim, Nagla Abdel Disease/Disorder overview Jan 1, 2018 3229
Noninferiority of [sup.99m]Tc-Ethylenedicysteine-Glucosamine as an Alternative Analogue to [sup.18]F-Fluorodeoxyglucose in the Detection and Staging of Non-Small Cell Lung Cancer. Dai, Dong; Rollo, F. David; Bryant, Jerry; Kim, E. Edmund Jan 1, 2018 5419
Label-Free Detection of Human Serum Using Surface-Enhanced Raman Spectroscopy Based on Highly Branched Gold Nanoparticle Substrates for Discrimination of Non-Small Cell Lung Cancer. Cao, Xiaowei; Wang, Zhenyu; Bi, Liyan; Zheng, Jie Jan 1, 2018 7306
Ability obtains US FDA approval to proceed with phase 1/2a clinical trial of ABTL0812 for endometrial cancer or squamous non-small cell lung cancer. Dec 14, 2017 305
Ability obtains US FDA approval to proceed with phase 1/2a clinical trial of ABTL0812 for endometrial cancer or squamous non-small cell lung cancer. Dec 14, 2017 301
Comparative Evaluation of Mediastinal Lymph Nodes in Non-small Cell Lung Cancer with Computed Tomography, 99mTc-MIBI SPECT, and Video-Mediastinoscopy. Onal, Omer; Demir, Omer Faruk Clinical report Dec 1, 2017 3991
United Kingdom : AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan. Nov 28, 2017 115
Japan : Chugai's ALK Inhibitor "Alecensa" Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US. Nov 9, 2017 321
Roche wins US FDA for VENTANA ALK (D5F3) CDx Assay to identify ALK-positive non-small cell lung cancer (NSCLC) patients. Nov 8, 2017 267
Roche wins US FDA for VENTANA ALK (D5F3) CDx Assay to identify ALK-positive non-small cell lung cancer (NSCLC) patients. Nov 8, 2017 263
Japan : Chugai's ALK Inhibitor "Alecensa" Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US. Nov 8, 2017 321
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer. Nov 2, 2017 388
Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Tezel, Gaye Guler; Sener, Ebru; Aydin, Cisel; Onder, Sevgen Nov 1, 2017 3095
Bristol-Myers Squibb Study Shows Opdivo Combined with Yervoy Doubles ORR Compared to Opdivo Alone in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden. Oct 17, 2017 448
United States : Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032. Oct 17, 2017 469
United States : Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer. Oct 17, 2017 837
United States : Thermo Fisher Scientific's Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan. Oct 17, 2017 324
EMA accepts MAA for Imfinzi in locally-advanced unresectable non-small cell lung cancer. Oct 9, 2017 181
Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer. Bagheri, Abouzar; Khorshid, Hamid Reza Khorram; Mowla, Seyed Javad; Mohebbi, Hassan A.N.; Mohammadia Report Oct 1, 2017 5088
AbbVie, Bristol-Myers Squibb Partner to Evaluate Combination of Antibody Drug Conjugate and Opdivo in Non-small Cell Lung Cancer. Sep 25, 2017 332
United States : Pfizer Presents Overall Survival Data of Xalkori in Patients With Alk-positive Advanced Non-small Cell Lung Cancer. Sep 12, 2017 376
United States : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Sep 11, 2017 409
Pfizer Presents Overall Survival Data of Xalkori in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. Sep 11, 2017 320
Thermal Ablation in the Management of Adrenal Metastasis Originating from Non-small Cell Lung Cancer: A 5-year Single-center Experience. Botsa, Evanthia; Thanou, Ioanna; Papatheodoropoulou, Aspasia; Thanos, Loukas Report Sep 1, 2017 3228
[sup]18F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group 1 and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer. Hu, Na; Wang, Yun-Hua; Li, Dai-Qiang; Yang, Xiao-Huang; Tan, Yan-Lin Report Sep 1, 2017 1145
Israel : Life-Prolonging Treatment for Metastatic Non-Small Cell Lung Cancer Approved for Clinical Trials. Sep 1, 2017 422
UT Southwestern Medical Center Researcher to Use Biocept Liquid Biopsy Tests for Detection of ALK Rearrangements in Clinical Study of Non-Small Cell Lung Cancer. Clinical report Aug 18, 2017 368
Kadmon Receives Orphan Drug Designation for Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer. Aug 8, 2017 236
United States : Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer. Aug 2, 2017 371
EC approves first-line use of Novartis' Zykadia in ALK-positive advanced non-small cell lung cancer. Jun 29, 2017 231
Thermo Fisher receives US FDA premarket approval for its Oncomine Dx Target Test for non-small cell lung cancer detection. Jun 23, 2017 278
Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis. Gokcal, Elif; Gursoy, Azize Esra; Asil, Talip; Ertas., Mustafa Report Jun 1, 2017 937
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 278
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 274
Switzerland : Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC). May 29, 2017 440
Determination Of Dna Methylation Status For 70 Small Cell Lung Cancer Panel Of Cell Lines Using The Illumina 850k Dna Methylation Array. May 14, 2017 105
FDA Approves US Merck's Keytruda as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression. May 10, 2017 390
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes, Clinical Pipeline and Forecast to 2021, New Report by iHealthcareAnalyst, Inc.. May 6, 2017 724
France,United States : Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer. Apr 28, 2017 376
United States : Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003. Report Apr 4, 2017 353
Switzerland : Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC). Apr 4, 2017 440
AstraZeneca passes US FDA approval for TAGRISSO tablets in 80mg for the treatment of non-small cell lung cancer. Apr 3, 2017 249
AstraZeneca passes US FDA approval for TAGRISSO tablets in 80mg for the treatment of non-small cell lung cancer. Apr 3, 2017 245
Spectrum Pharmaceuticals Launches Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Mar 31, 2017 292
Forecasters predict APAC non-small cell lung cancer market will double. Mar 21, 2017 301
Forecasters predict APAC non-small cell lung cancer market will double. Mar 21, 2017 297
Biocept, Catalyst Pharmaceuticals Team on Liquid Biopsy Testing for Small Cell Lung Cancer. Mar 15, 2017 454
Foundation Medicine announces coverage and payment in non-small cell lung cancer under Palmetto GBA's LCD. Mar 3, 2017 160
Foundation Medicine announces coverage and payment in non-small cell lung cancer under Palmetto GBA's LCD. Mar 3, 2017 156
Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer Assay in North Carolina. Mar 3, 2017 239
Non-Small Cell Lung Cancer (NSCLC) Market to Reach USD 26.71bn by 2025, Research and Markets Forecasts. Feb 27, 2017 279
EC Approves US Merck's Keytruda for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer When Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations. Feb 1, 2017 332
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 326
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 322
CACNA1B ([Ca.sub.v]2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer. Zhou, Xiaoyu; Wang, Wei; Zhang, Shu; Wang, Xudong; Tang, Zhiyuan; Gu, Jun; Li, Jun; Huang, Jianan Report Jan 1, 2017 4787
Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. Huang, Bao-Tian; Zhang, Wu-Zhe; Wu, Li-Li; Lin, Pei-Xian; Lu, Jia-Yang Report Jan 1, 2017 5838
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Jiang, Wei; Zhang, Wenjue; Wu, Lihong; Liu, Lipin; Men, Yu; Wang, Jingbo; Liang, Jun; Hui, Zhouguang Report Jan 1, 2017 5433
Refractory Lactic Acidosis in Small Cell Carcinoma of the Lung. Oh, Daniel J.; Dinerman, Ellen; Matthews, Andrew H.; Aron, Abraham W.; Berg, Katherine M. Clinical report Jan 1, 2017 1609
Altered Brain Functional Connectivity in Small-Cell Lung Cancer Patients after Chemotherapy Treatment: A Resting-State fMRI Study. Bromis, Konstantinos; Gkiatis, Kostakis; Karanasiou, Irene; Matsopoulos, George; Karavasilis, Eustra Report Jan 1, 2017 6303
Geographical Variation and Factors Associated with Non-Small Cell Lung Cancer in Manitoba. Dawe, David E.; Singh, Harminder; Wickramasinghe, Lahiru; Pitz, Marshall W.; Torabi, Mahmoud Report Jan 1, 2017 6416
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 311
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 307
Genentech, a member of the Roche Group, received approval from the FDA for TECENTRIQ (atezolizumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following chemotherapy, and have progressed on another targeted therapy if their tumor has EGFR or ALK gene abnormalities. Nov 1, 2016 172
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Dolled-Filhart, Marisa; Roach, Charlotte; Toland, Grant; Stanforth, Dave; Jansson, Malinka; Lubiniec Nov 1, 2016 5096
United States : Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer. Oct 10, 2016 146
Japan : Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer. Oct 7, 2016 463
United States : CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer. Clinical report Sep 9, 2016 213
United States : FDA accepts Supplemental Biologics License Application, assigns Priority Review and Grants Breakthrough Therapy Designation to Mercks KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer. Sep 8, 2016 355
United States : XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. Sep 1, 2016 437
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 266
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 262
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 256
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 252
Non-Small Cell Lung Cancer Therapeutics Market to Reach USD 10.5 Billion by 2020, Recent Findings by iHealthcareAnalyst, Inc.. Aug 8, 2016 595
United States : Mercks KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1. Aug 3, 2016 270
Spain : PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer. Report Aug 3, 2016 280
Bristol-Myers Squibb partners with Janssen for non-small cell lung cancer. Jul 26, 2016 240
Bristol-Myers Squibb partners with Janssen for non-small cell lung cancer. Jul 26, 2016 236
United States : Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC). Jun 8, 2016 688
Medical Affairs Reputations Non-small Cell Lung Cancer EU5 - New Study Released. Jun 8, 2016 511
United States : Pfizer presents Promising Data From Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer. Jun 7, 2016 589
New Market Report: Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022. Jun 7, 2016 535
New market study, "Medical Affairs Reputations Non-small Cell Lung Cancer US", has been published. Jun 5, 2016 509
United States : FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer. Jun 2, 2016 618
Daiichi Sankyo Provides HER3-Lung study update for Patritumab in Non-Small Cell Lung Cancer. Jun 1, 2016 310
Daiichi Sankyo Provides HER3-Lung study update for Patritumab in Non-Small Cell Lung Cancer. Jun 1, 2016 306
United States : New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer. May 17, 2016 376
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 360
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 356
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 200
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 196
United States : Tagrisso (osimertinib) approved in Japan for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Mar 30, 2016 496
United States : XALKORI Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. Mar 14, 2016 514
United States : FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. Mar 12, 2016 618
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Kerr, Keith M.; Nicolson, Marianne C. Mar 1, 2016 5316
New market study, "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015", has been published. Feb 9, 2016 489
United Kingdom : TAGRISSO (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Feb 4, 2016 659
Delaying chemotherapy in the treatment of stage IV non-small cell lung cancer does not adversely affect survival outcome. Mozayen, Mohammad; Alsharedi, Mohamed; Mehmi, Inderjit; Gress, Todd; Tirona, Maria Tria Report Jan 1, 2016 2424
Mirati Therapeutics doses first Non-Small Cell Lung Cancer patient in MGCD516 Phase 1b clinical trial. Dec 21, 2015 192
Mirati Therapeutics doses first Non-Small Cell Lung Cancer patient in MGCD516 Phase 1b clinical trial. Dec 21, 2015 188
United States : TAGRISSO (osimertinib) receives positive CHMP opinion for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Dec 19, 2015 553
United States : FDA approves Portrazza to treat advanced squamous non-small cell lung cancer. Nov 26, 2015 410
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 284
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 285
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 280
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 281
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - New Study. Nov 23, 2015 448
Diplomat Pharmacy to market the oral therapy TAGRISSO for specific metastatic non-small cell lung cancer. Nov 17, 2015 214
Diplomat Pharmacy to market the oral therapy TAGRISSO for specific metastatic non-small cell lung cancer. Nov 17, 2015 218
United States : FDA approves new pill to treat certain patients with non-small cell lung cancer. Nov 14, 2015 748
United States : TAGRISSO (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Nov 14, 2015 597
Newly released market study: Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019. Nov 6, 2015 464
Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer. Report Oct 31, 2015 3078
Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015 - New Report Available. Oct 13, 2015 486
Dako wins US FDA approval to support use of OPDIVO for non-squamous non-small cell lung cancer. Oct 12, 2015 243
Dako wins US FDA approval to support use of OPDIVO for non-squamous non-small cell lung cancer. Oct 12, 2015 239
United States : FDA approves Keytruda for advanced non-small cell lung cancer. Oct 3, 2015 787
Diplomat to introduce IRESSA as a first-line treatment for selected patients with metastatic non-small cell lung cancer. Aug 11, 2015 261
Diplomat to introduce IRESSA as a first-line treatment for selected patients with metastatic non-small cell lung cancer. Aug 11, 2015 257
Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. Deeb, Kristin K.; Hohman, Colleen M.; Risch, Nicholas F.; Metzger, Daniel J.; Starostik, Petr Jul 1, 2015 5826
AmoyDx, Supplier of MoBiTec, Germany, Introduces System for Extraction of Circulating DNA from NSCLC (Non-Small Cell Lung Cancer) Patients. Jun 26, 2015 383
A rare case of small cell lung cancer with skin metastases. Acharya, Preetam R.; Kanchan, Tanuj; Rai, Santosh May 18, 2015 1521
Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Han, Shu-Yan; Zhao, Wei; Sun, Hong; Zhou, Ning; Zhou, Fei; An, Guo; Li, Ping-Ping Report May 15, 2015 4727
Switzerland : U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer. Feb 4, 2015 359
United States : U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer. Feb 2, 2015 289
U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer. Feb 2, 2015 808
The role of Positron Emission Tomography in mediastinal staging of patients with non-small cell lung cancer. Clinical report Jan 31, 2015 2274
ERCC1 RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy. Dec 31, 2014 3201
United States : FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer. Dec 13, 2014 457
Germany : New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF (afatinib) compared to chemoth. Nov 10, 2014 430
Bristol-Myers Squibb Company's MAA for Nivolumab under EMA review for non-small cell lung cancer. Sep 30, 2014 218
Global Non-small Cell Lung Cancer Market 2014-2018 - New Market Research Report. Sep 30, 2014 438
Bristol-Myers Squibb Company's MAA for Nivolumab under EMA review for non-small cell lung cancer. Sep 30, 2014 222
Report Published on the Non-Small Cell Lung Cancer Market to 2020. Sep 18, 2014 411
Response Genetics launches new non-small cell lung cancer testing programme. Sep 15, 2014 372
Germany : Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer. Sep 13, 2014 329
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Jun 30, 2014 3353
Immunohistochemistry, Fluorescence in Situ Hybridization, and Reverse Transcription-Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Patients With Non-Small Cell Lung Cancer: Potential Advantages and Methodologic Pitfalls. Demidova, Irina; Barinov, Aleksei; Savelov, Nikita; Gagarin, Ilia; Grinevitch, Viacheslav; Stroiakov Jun 1, 2014 6889
The Lancet Oncology features positive study data for Biodesix's VeriStrat test in non-small cell lung cancer. Clinical report May 13, 2014 254
United Kingdom : Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. Apr 3, 2014 422
United Kingdom : Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial. Mar 21, 2014 379
United Kingdom : Tafinlar receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation. Jan 14, 2014 298
In silico screening of mutated K-ras inhibitors from Malaysian Typhonium flagelliforme for non-small cell lung cancer. Fatima, Ayesha; Yee, H.F. Jan 1, 2014 4141
Conjunctival metastasis as an initial sign of small cell lung cancer. Sahin, Afsun; Yildirim, Nilgun; Sahin, Deniz Goren; Basmak, Hikmet; Acikalin, Mustafa Case study Jan 1, 2014 908
Axelar reports final results from Phase II study with AXL1717 in patients with non-small cell lung cancer. Clinical report Dec 30, 2013 151
Axelar reports final results from Phase II study with AXL1717 in patients with non-small cell lung cancer. Clinical report Dec 30, 2013 147
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 235
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 231
Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer. Oct 31, 2013 2893
Biodesix unveils mixed Phase III results for VeriStrat test in non-small cell lung cancer. Clinical report Oct 29, 2013 189
Japan : New Drug Application Filed for ALK Inhibitor Alectinib Hydrochloride for the Treatment of ALK Fusion Gene Positive Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer. Oct 9, 2013 415
Now Available: Non-Small Cell Lung Cancer - Pipeline Review, H2 2013. Sep 25, 2013 880
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Ruschoff, Josef; Kerr, Keith M.; Grote, Hans J.; Middel, Peter; von Heydebreck, Anja; Alves, Venanci Report Sep 1, 2013 5302
Switzerland : Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer. Jun 4, 2013 434
Germany : Merck Serono: Detailed Results of Phase III Trial of L-BLP25 in Patients With Non-Small Cell Lung Cancer (START) to be Presented at ASCO. May 17, 2013 460
i"?OncoMed Pharmaceuticals starts Phase 1b/2 trial of OMP-59R5 (Anti-Notch2/3) in small cell lung cancer patients. May 16, 2013 141
i"?OncoMed Pharmaceuticals starts Phase 1b/2 trial of OMP-59R5 (Anti-Notch2/3) in small cell lung cancer patients. May 16, 2013 137

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters